Described are novel N- and C-terminally double truncated tau molecules, (“type IA, IB, IIA and IIB tau molecules”) as well as methods for providing these molecules, both from recombinant and biological sources. Moreover, screening methods using these molecules in connection with Alzheimers diagnosis and therapy are provided.
